Biomedical importance of indoles

Molecules

Volumn 18, Issue 6, 2013, Pages 6620-6662

  Kaushik, Nagendra Kumar ^a   Kaushik, Neha ^a   Attri, Pankaj ^a   Kumar, Naresh ^a   Kim, Chung Hyeok ^a   Verma, Akhilesh Kumar ^b   Choi, Eun Ha ^a  

^a Kwangwoon University   (South Korea)

^b UNIVERSITY OF DELHI   (India)

Author keywords

Bioactivity; Biomedical application; Indole; Pharmacological activity

Indexed keywords

DRUG; INDOLE DERIVATIVE;

CHEMISTRY; DRUG DEVELOPMENT; REVIEW; SYNTHESIS;

DRUG DISCOVERY; INDOLES; PHARMACEUTICAL PREPARATIONS;

EID: 84879663171     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18066620     Document Type: Review

References (132)

1. Dolle, R.E.; Nelson, K.H. Comprehensive survey of combinatorial library synthesis: 1998. J. Comb. Chem. 1999, 1, 235-282.
2. Franzen, R.G. Recent advances in the preparation of heterocycles on solid support: A review of the literature. J. Comb. Chem. 2000, 2, 195-214.
3. Dolle, R.E. Comprehensive survey of combinatorial library synthesis: 2000. J. Comb. Chem. 2001, 3, 477-517.
4. Hanessian, S.; McNaughton-Smith, G.; Lombart, H.G.; Lubell, W.D. Design and synthesis of conformationally constrained amino acids as versatile scaffolds and peptide mimetics. Tetrahedron 1997, 53, 12789-12854.
5. Radwanski, E.R; Last, R.L. Tryptophan biosynthesis and metabolism: Biochemical and molecular genetics. Plant Cell 1995, 7, 921-934.
6. Jones R.S. Tryptamine: A neuromodulator or neurotransmitter in mammalian brain? Progress Neurobiol. 1982, 19, 117-139.
7. Berger, M.; Gray, J.A.; Roth, B.L. The expanded biology of serotonin. Annu. Rev. Med. 2009, 60, 335-366.
8. Chilton, W.S.; Bigwood, J.; Gensen, R.E. Psilocin, bufotenine and serotonin: Historical and biosynthetic observations. J. Psychedelic Drugs 1979, 11, 61-69.
9. Freidonk-Mueschenborn, E.; Fox, A. Resolution of concentration-response differences in onset of effect between subcutaneous and oral sumatriptan. Headache 2005, 45, 632-637.
10. Generali, J.A.; Cada, D.J. Off-label drug uses-Ondansetron: Postanesthetic shivering. Hospital Pharmacy 2009, 44, 670-671.
11. Horton, R. Lotronex and the FDA: A fatal erosion of integrity. Lancet 2001, 375, 1544-1545.
12. Saxton, J.E. Monoterpenoid indole alkaloids. In The Chemistry of Heterocyclic Compounds Part 4; John Wiley & Sons: Hoboken, NJ, USA, 2008.
13. Mehta, R.G.; Liu, J.; Constantinou, A.; Thomas, C.F.; Hawthorne, M.; You, M.; Gerhüser, C.; Pezzuto, J.M.; Moon, R.C.; Moriarty, R.M. Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage. Carcinogenesis 1995, 16, 399-404.
14. Cohen, S. The Beyond Within: The LSD Story; Atheneum: New York, NY, USA, 1964.
15. Ferreira, S.; Moncada, S.; Vane, J. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat. New Biol. 1971, 231, 237-239.
16. Johnson, I.S.; Armstrong, J.G.; Gorman, M.; Burnett, J.P. Jr. The Vinca Alkaloids: A new class of oncolytic agents. Cancer Res. 1963, 23, 1390-1427.
17. Duflos, A.; Kruczynski, A.; Barrat, J.M. Novel aspects of natural and modified vinca alkaloids. Curr. Med. Chem. Anticancer Agents 2002, 2, 55-70.
18. Beckers, T.; Mahboobi, S. Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy. Drugs Future 2003, 28, 767-785.
19. Bacher, G.; Beckers, T.; Emig, P.; Klenner, T.; Kutshert, B.; Nickel, B. New small-molecule tubulin inhibitors. Pure Appl. Chem. 2001, 73, 1459.
20. Beckers, T.; Baasner, S.; Klenner, T.; Mahboobi, S.; Pongratz, H.; Frieser, M.; Hufsky, H.; Hockemeyer, J.; Fiebig, H.H.; Burger, A.; Bohmer, F.D. 2-Acyl indol derivatives and their use as antitumor agents. WO/2001/082909, 8 November 2001.
21. Gastpar, R.; Goldbrunner, M.; Marko, D.; von Angere, E. Methoxy-substituted 3-formyl-2- phenylindoles inhibit tubulin polymerization. J. Med. Chem. 1998, 41, 4965-4972.
22. Medarde, M.; Ramos, A.; Caballero, E.; Peláz-Lamamié de Clairac, R.; López, J.L.; Garciá Gravalos, D.; San Felicia, A. Synthesis and antineoplastic activity of combretastatin analogues: Heterocombretastatins. Eur. J. Med. Chem. 1998, 33, 71-77.
23. Flynn, B.L.; Hamel, E.; Jung, M.K. One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. J. Med. Chem. 2002, 45, 2670-2673.
24. Yamamoto, K.; Noda, K.; Yoshimura, A.; Kukuoka, M.; Furuse,K.; Niitani, H. Phase-I Study of E7010. Cancer Chem. Pharmacol. 1998, 42, 127-134.
25. Flynn, B.L.; Flynn, G.P.; Hamel, E.; Jung, M.K. The synthesis and tubulin binding activity of thiophene-based analogues A-4 combretastatin. Bioorg. Med. Chem. Lett. 2001, 11, 2341-2343.
26. Bos, M.; Jenck, F.; Martin, J.R.; Moreau, J.L.; Mutel, V.; Sleight, A.J.; Widmer, U. Synthesis, pharmacology and therapeutic potential of 10-methoxypyrazino[1,2-a]indoles, partial agonists at the 5HT2C receptor. Eur. J. Med. Chem. 1997, 32, 253-261.
27. Hudson, A.L.; Price, R.; Tyacke, R.J.; Lalies, M.D.; Parker, C.A. and Nutt, D.J. Harmane, norharmane and tetrahydro β-carboline have high affinity for rat imidazoline binding sites. Br. J. Pharmacol. 1999, 126, 2P.
28. Husbands, S.M.; Glennon, R.A.; Gorgerat, S.; Gough, R.; Tyacke, R.; Crosby, J.; Nutt, D.J.; Lewis, J.W. and Hudson, A.L. β-carboline binding to imidazoline receptors. Drug Alcohol. Depend. 2001, 64, 203-208.
29. Escude, C.; Nguyen, C-H.; Mergny, J-L.; Sun, J-S.; Bisagni, E.; Garestier, T.; Helene, C. Selective Stabilization of DNA Triple Helixes by Benzopyridoindole Derivatives. J. Am. Chem. Soc. 1995, 117, 10212-10219.
30. Johnson, J.R.; Bruce, W.F.; Dutcher, J.D. Gliotoxin, the antibiotic principle of gliocladium fimbriatum. I. production, physical and biological properties. J. Am. Chem. Soc. 1943, 65, 2005-2009.
31. Fridrichsons, J.; Mathieson, A.M. The crystal structure of gliotoxin. Acta. Crystallogr. 1967, 23, 439-448.
32. Hara, M.; Han, M. Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA 1995, 92, 3333-3337.
33. Nagase, T.; Kawata, S.; Tamura, S.; Matsuda, Y.; Inui, Y.; Yamasaki, E.; Ishiguro, H.; Ito, T.; Miyagawa, J.; Mitsui, H.; Yamamoto, K.; Kinoshita, M.; Matsuzawa, Y. Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells. Br. J. Cancer 1997, 76, 1001-1010.
34. Van der Pyl, D.; Inokoshi, J.; Shiomi, K.; Yang, H.; Takeshima, H.; Omura, S. Inhibition of farnesyl-protein transferase by gliotoxin and acetylgliotoxin. J. Antibiot. 1992, 45, 1802-1805.
35. Stiborova, M.; Bieler, C. A.; Wiessler, M.; Frei, E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem. Pharmacol. 2001, 62, 1675-1684.
36. Auclair C. Multimodal action of antitumor agents on DNA: the ellipticine series. Arch. Biochem. Biophys. 1987, 259, 1-14.
37. Frei, E; Bieler, C.A.; Arlt, V.M.; Wiessler, M.; Stiborova, M. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem. Pharmacol. 2002, 64, 289-295.
38. Stiborova, M.; Stiborova-Rupertova, M.; Borek-Dohalska, L.; Wiessler, M.; Frei, E. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem. Res. Toxicol. 2003, 16, 38-47.
39. Stiborova, M.; Breuer, A.; Aimova, D.; Stiborová-Rupertová, M.; Wiessler, M.; Frei, E. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling. Int. J. Cancer 2003, 107, 885-890.
40. Murray, G.I.; Weaver, R.J.; Paterson, P.J.; Ewen, S.W.B.; Melvin, W.T.; Danny, M.B. Expression of xenobiotic metabolizing enzymes in breast cancer. J. Pathol. 1993, 169, 347-353.
41. Borek-Dohalska, L.; Frei, E.; Stiborova, M. DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 Cells. Collect Czech Chem. Commun. 2004, 69, 603-615.
42. Campbell J.A.; Bordunov, V.; Broke, C.A.; Dhankwardt, J.; Hendricks, R.T.; Kress, J.M.; Walker, K.A.M. and Wang J.H. Preparation of 3-arylmethylindoles as selective COX-2 inhibitors. Tetrahedron Lett. 2004, 45, 3793-3796.
43. Andersson K. E. Pharmacology of penile erection. Pharmacol. Rev. 2001, 53, 417-450.
44. Rosengren, A.H.; Jokubka, R.; Tojjar, D.; Granhall, C.; Hansson, O.; Li, D.Q.; Nagaraj, V.; Reinbothe, T.M.; Tuncel, J.; Eliasson, L.; et al. Overexpression of Alpha2A-Adrenergic receptors contributes to type 2 diabetes. Science 2009, 327, 217-220.
45. Scott, L.J.; Perry, C.M. Delavirdine: A review of its use in HIV infection. Drugs 2000, 60, 1411-1444.
46. Biswal, S.; Sahoo, U.; Sethy, S.; Kumar, H.K.S.; Banerjee, M. Indole: The molecule of diverse biological activities. Asian J. Pharm. Clin. Res. 2012, 5, 1.
47. Yutkin, V.; Chin, J. Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer. Expert Opin. Investig. Drugs. 2012, 21, 251-260.
48. Hall, Chapman; Rhodes, P.H. Dictionary of Organic Compounds; Chapman & Hall: London, UK, 1996.
49. Leneva, I.A.; Russell, R.J.; Boriskin, Y.S.;, Hay, A.J. Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009, 81, 132-140.
50. Napalkov, D.A. Therapy with perindopril: organoprotection, not just the antihypertensive effect. Kardiologiia 2012, 52, 80-83.
51. Bacher, N.; Tiefenthaler, M.; Sturm, S.; Stuppner, H.; Ausserlechner, M.J.; Kofler, R.; Konwalinka, G. Oxindole alkaloids from Uncaria tomentosa induce apoptosis in proliferating, G0/G1-arrested and bcl-2-expressing acute lymphoblastic leukaemia cells. Br. J. Haematol. 2006, 132, 615-622.
52. García Giménez, D.; García Prado, E.; Sáenz Rodríguez, T.; Fernández Arche, A.; de la Puerta, R. Cytotoxic effect of the pentacyclic oxindole alkaloid mitraphylline isolated from Uncaria tomentosa bark on human Ewing's sarcoma and breast cancer cell lines. Planta Med. 2010, 76, 133-136.
53. Prince, H.M.; Bishton M. Panobinostat (LBH589): A novel pan-deacetylase inhibitor with activity in T cell lymphoma. Hematol. Meet. Rep. 2009, 3, 33-38.
54. Mack, G.S. To selectivity and beyond. Nat. Biotech. 2010, 28, 1259-1266.
55. Isaac, M.T. Review: Combining pindolol with an SSRI improves early outcomes in people with depression. Evid. Based Ment. Health 2004, 7, 107.
56. Lednicer, D. The Organic Chemistry of Drug Synthesis; A John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2007; Volume 7, pp. 141-154.
57. Klimke A, Klieser E. Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study. Pharmacopsychiatry 1991, 24, 107-112.
58. Muller, W.; T. Stratz. Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron. Scand. J. Rheumatic Suppl. 2004, 119, 44-48.
59. Macor, J.E.; Gurley, D.; Lanthorn, T.; Loch, J.; Mack, R.A.; Mullen, G.; Tran, O.; Wright, N.; Gordon, J.C. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist. Bioorg. Med. Chem. Lett. 2001, 11, 319-321.
60. Cui, R. Suemaru, K.; Li, B.; Kohnomi, S.; Araki, H. Tropisetron attenuates naloxone-induced place aversion in single-dose morphine-treated rats: role of alpha7 nicotinic receptors. Eur. J. Pharma. 2009, 609, 74-77.
61. Morse, G.D.; Reichman, R.C.; Fischl, M.A.; Para, M.; Leedom, J.; Powderly, W.; Demeter, L.M. Resnick, L.; Bassiakos, Y.; Timpone, J.; Cox, S.; Batts, D. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. Antiviral Res. 2010, 45, 47-58.
62. Hart, F.; Boardman, P. Indomethacin: A New non-steroid anti-inflammatory agent. Br. Med. J. 1963, 2, 965-970.
63. Smyth, C. J. Indomethacin-Its rightful place in treatment. Ann. Intern. Med. 1970, 72, 430-432.
64. DrugBank.ca. Available online: http://www.drugbank.ca/drugs/DB00328 (accessed on 15 April 2013).
65. Arens, H.; Borbe, H.O.; Ulbrich, B.; Stöckigt, J. Detection of pericine, a new cns-active indole alkaloid from picralima nitida cell suspension culture by opiate receptor binding studies. Planta Med. 1982, 46, 210-214.
66. Roberts, M.F.; Wink, M. Alkaloids: Biochemistry, Ecology, and Medicinal Applications; Plenum Press: New York, NY, USA, 1998.
67. Haubrich, D.R.; Ward, S.J. Baizman, E.; Bell, M.R.; Bradford, J.; Ferrari, R.; Miller, M.; Perrone, M.; Pierson, A.K.; Saelens, J.K.; et al. Pharmacology of pravadoline: A new analgesic agent. J. Pharmacol. Exp. Ther. 1990, 255, 511-522.
68. Bell, M.R.; D'Ambra, T.E.; Kumar, V.; Eissenstat, M.A.; Herrmann, J.L.; Wetzel, J.R., Jr; Rosi, D.; Philion, R.E.; Daum, S.J.; Hlasta, D.J.; et al. Antinociceptive (aminoalkyl) indoles. J. Med. Chem. 1991, 34, 1099-1110.
69. Cook, P.; James, I. Cerebral Vasodilators. N. Engl. J. Med. 1981, 305, 1560-1564.
70. Arpe, H-J; Ullmann, F. Indole Alkaloids. In Ullmann's Encyclopedia of Industrial Chemistry, 5th ed.; Wiley-VCH: Weinheim, Germany, 1985.
71. Lynn, A.; Collins, A.; Fuller, Z.; Hillman, K; Ratcliffe, B. Cruciferous vegetables and colo-rectal cancer. Proc. Nutr. Soc. 2006, 65, 135-144.
72. Dashwood, R. H.; Arbogast, D. N.; Fong, A. T.; Pereira, C.; Hendricks, J.D.; Bailey, G.S. Quantitative inter-relationships between aflatoxin B1 carcinogen dose, indole-3-carbinol anti-carcinogen dose, target organ DNA adduction and final tumor response. Carcinogenesis 1989, 10, 175-181.
73. Ho, J.N.; Jun, W.; Choue, R.; Lee, J. I3C and ICZ inhibit migration by suppressing the EMT process and FAK expression in breast cancer cells. Mol. Med. Rep. 2012, 7, 384-388.
74. Chang, X.; Tou, J. C.; Hong, C.; Kim, H.A.; Riby, J.E.; Firestone, G.L.; Bjeldane, L.F. 3,3'-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis 2005, 26, 771-778.
75. Rahman, K.M.W.; Li Y.; Wang, Z.; Sarkar, S.H.; Sarkar, F.H. Gene expression profiling revealed survivin as a target of 3,3'-Diindolylmethane- induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res. 2006, 66, 4952-4960.
76. Benninghoff, A.D.; Williams, D.E. The role of estrogen receptor β in transplacental cancer prevention by indole-3-Carbinol. Cancer Prev. Res. 2013, 6, 339-348.
77. Liu, A.G.; Volker, S.E.; Jeffery, E.H.; Erdman, J.W., Jr. Feeding tomato and broccoli powders enriched with bioactives improves bioactivity markers in rats. J. Agric. Food Chem. 2009, 57, 7304-7310.
78. Kim, Y.S.; Milner, J.A. Targets for indole-3-carbinol in cancer prevention. J. Nutr. Biochem. 2005, 16, 65-73.
79. Shorey, L.E.; Hagman, A.M.; Williams, D.E.; Ho, E.; Dashwood, R.H.; Benninghoff, A.D. 3,3'- Diindolylmethane induces G1 arrest and apoptosis in human acute T-Cell lymphoblastic leukemia cells. PLoS One 2012, 7, e34975.
80. Tsai, J.T.; Liu, H.C.; Chen, Y.H. Suppression of inflammatory mediators by cruciferous vegetable-derived indole-3-carbinol and phenylethyl isothiocyanate in lipopolysaccharideactivated macrophages. Mediat. Inflamm. 2010, 2010, 293642.
81. Zhang, S.; Li, Z.; Wu, X.; Huang, Q.; Shen, H.M.; Ong, C.N. Methyl-3-indolylacetate inhibits cancer cell invasion by targeting the MEK1/2-ERK1/2 signaling pathway. Mol. Cancer Ther. 2006, 5, 3285-3293.
82. Jeffery, E.H.; Araya, M. Physiological effects of broccoli consumption. Phytochem. Rev. 2009, 8, 283-298.
83. Shin, J.S.; Yun, C.H.; Cho, Y.W.; Baek, N.I.; Choi, M.S.; Jeong, T.S.; Chung, H.G.; Lee, K.T. Indole-containing fractions of Brassica rapa inhibit inducible nitric oxide synthase and pro-inflammatory cytokine expression by inactivating nuclear factor-κB. J. Med. Food. 2011, 14, 1527-1537.
84. Fernández-Pérez, F.; Almagro, L.; Pedreño, M.A.; GómezRos, L.V. Synergistic and cytotoxic action of indole alkaloids produced from elicited cell cultures of catharanthus roseus. Pharm. Biol. 2013, 51, 304-310.
85. Yu, H.; Jin, H.; Gong, W.; Wang, Z.; Liang, H. pharmacological actions of multi-target-directed evodiamine. Molecules 2013, 18, 1826-1843.
86. Shittu, H.; Gray, A.; Furman, B.; Young, L. Glucose uptake stimulatory effect of akuammicine from Picralima nitida (Apocynaceae). Phytochem. Lett. 2010, 3, 53-55.
87. Ruiz-Sanchis, P.; Savina, S.A.; Albericio, F.; Álvarez, M. Structure, bioactivity and synthesis of natural products with hexahydropyrrolo[2,3-b]indole. Chem. Eur. J. 2011, 17, 1388-1408.
88. Bialonska, D.; Zjawiony, J.K. Aplysinopsins-Marine indole alkaloids: Chemistry, bioactivity and ecological significance. Mar. Drugs 2009, 7, 166-183.
89. Longeon, A.; Copp, B.R.; Quévrain, E.; Roué, M.; Kientz, B.; Cresteil, T.; Petek, S.; Debitus, C.; Bourguet-Kondracki, M.L. Bioactive indole derivatives from the south pacific marine sponges rhopaloeides odorabile and hyrtios sp. Mar. Drugs. 2011, 9, 879-888.
90. Bharate, S.B.; Manda, S.; Mupparapu, N.; Battini, N.; Vishwakarma, R. A chemistry and biology of fascaplysin, a potent marine-derived CDK-4 inhibitor. Mini. Rev. Med. Chem. 2012, 12, 650-664.
91. Mollica, A.; Locatelli M.; Stefanucci, A.; Pinnen, F. Synthesis and bioactivity of secondary metabolites from marine sponges containing dibrominated indolic systems. Molecules 2012, 17, 6083-6099.
92. Yang, X.W.; Zhang, G.Y.; Ying, J.X.; Yang, B.; Zhou, X.F.; Steinmetz, A.; Liu, Y. H.; Wang, N. Isolation, Characterization, and bioactivity evaluation of 3-((6-Methylpyrazin-2-yl)methyl)-1Hindole, a new alkaloid from a deep-sea-derived actinomycete Serinicoccus profundi sp. nov. Mar. Drugs 2013, 11, 33-39.
93. Baker, J.T. Tyrian purple: An ancient dye, a modern problem. Endeavour 1974, 33, 11-17.
94. Baker, J.; Duke, C. Chemistry of the indoleninones. II. Isolation from the hypobranchial glands of marine molluscs of 6-bromo-2,2-dimethylthioindolin- 3-one and 6-bromo-2-methylthioindoleninone as alternative precursors to Tyrian purple. Aust. J. Chem. 1973, 26, 2153-2157.
95. Westley, C.B.; Lewis, M.C.; Benkendorff, K. Histomorphology of the hypobranchial gland in Dicathais orbita (Gmelin, 1791) (Neogastropoda: Muricidae). J. Moll. Stud. 2010, 76, 186-195.
96. Benkendorff, K. Natural product research in the australian marine invertebrate dicathais orbita. Mar. Drugs 2013, 11, 1370-1398.
97. Devi, P.; Wahidullah, S.; Rodrigues, C.; Souza, L.D. The Sponge-associated bacterium bacillus licheniformis SAB1: A source of antimicrobial compounds. Mar. Drugs 2010, 8, 1203-1212.
98. Mandal, D.; Yamaguchi, A.D.; Yamaguchi, J.; Itami, K. Synthesis of dragmacidin D via direct C-H couplings. J. Am. Chem. Soc. 2011, 133, 19660-19663.
99. Chen, M.; Shao, C.L.; Fu, X.M.; Xu, R.F.; Zheng, J.J.; Zhao, D.L.; She, Z.G.; Wang, C.Y. Bioactive indole alkaloids and phenyl Ether derivatives from a marine-derived aspergillus sp. fungus. J. Nat. Prod. 2013, 76, 547-553.
100. Perchellet, J.P.; Waters, A.M.; Perchellet, E.M.; Thornton, P.D.; Brown, N.; Hill, D.; Neuenswander, B.; Lushington, G.H.; Santini, C.; Chandrasoma, N.; Buszek, K.R. Antitumor effects of synthetic 6,7-annulated-4-substituted indole compounds in L1210 leukemic cells in vitro. Anticancer. Res. 2012, 32, 4671-4684.
101. Thornton, P.D.; Brown, N.; Hill, D. Neuenswander, B.; Lushington, G. H.; Santini, C.; Buszek, K.R. Application of 6,7-indole aryne cycloaddition and Pd(0)-catalyzed Suzuki-Miyaura and Buchwald-Hartwig cross-coupling reactions for the preparation of annulated indole libraries. ACS Comb. Sci. 2011, 13, 443-448.
102. Xie, C.; Zhou, J.; Guo, Z.; Diao, X.; Gao, Z.; Zhong, D.; Jiang, H.; Zhang, L.; Chen, X. Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br. J. Pharmacol. 2013, 168, 1687-1706.
103. Roy, S.; Eastman, A.; Gribble, G. W. Synthesis of bisindolylmaleimides related to GF109203x and their efficient conversion to the bioactive indolocarbazoles. Org. Biomol. Chem. 2006, 4, 3228-3234.
104. Zhang, Q.; Peng, Y.; Wang, X.I.; Keenan, S.M.; Arora, S.; Welsh, W.J. Highly potent triazolebased tubulin polymerization inhibitors. J. Med. Chem. 2007, 50, 749-754.
105. Jump, S.M.; Kung, J.; Staub, R.; Kinseth, M.A.; Cram, E.J.; Yudina, L.N.; Preobrazhenskaya, M.N.; Bjeldanes, L.F.; Firestone, G.L. N-Alkoxy derivatization of indole-3-carbinol increases the efficacy of the G1 cell cycle arrest and of I3C-specific regulation of cell cycle gene transcription and activity in human breast cancer cells. Biochem. Pharmacol. 2008, 75, 713-724.
106. Sharma, P.; Kumar, A.; Sahu, V.; Upadhyay, S.; Singh, J. Synthesis of bioactive spiro-2-[3'-(2'- phenyl)-3H-indolyl]-1-aryl-3-phenylaziridines and SAR studies on their antimicrobial behavior. Med. Chem. Res. 2009, 18, 383-395.
107. Chen, G.; Hao, X.J.; Sun, Q.Y.; Ding, J. Rapid synthesis and bioactivities of 3-(nitromethylene)indolin-2-one analogues. Chem. Pap. 2010, 64, 673-677.
108. Pessoa-Mahana, H.; Cuevas, M.I.; Pessoa-Mahana, C.D.; Araya-Maturana, R.; Fazardo, I.A.; Barria, C.S. Synthesis of 1-benzyl-3-[4-(aryl-1-piperazinyl) carbonyl]-1H-indoles.Novel ligands with potential D4 dopaminergic activity. J. Chil. Chem. Soc. 2011, 56, 866-869.
109. Hosseinnia, R; Mamaghani, M; Tabatabaeian, K; Shirini, F; Rassa, M. An expeditious regioselective synthesis of novel bioactive indole-substituted chromene derivatives via one-pot three-component reaction. Bioorg. Med. Chem. Lett. 2012, 22, 5956-5960.
110. Zhang, Y.; Yang, P.; Chou, C.J.; Liu, C.; Wang, X.; Xu, W. Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with an Indole-Containing Cap Group. ACS Med. Chem. Lett. 2013, 4. 235-238.
111. Akkoc, M.K.; Yuksel, M.Y.; Durmaz, I.; Atalay, R.C. Design, synthesis, and biological evaluation of indole-based 1,4-disubstituted piperazines as cytotoxic agents. Turk. J. Chem. 2012, 36, 515-525.
112. Singh, P.; Kaur, M.; Verma, P. Design, synthesis and anticancer activities of hybrids of indole and barbituric acids-Identification of highly promising leads. Bioorg. Med. Chem. Lett. 2009, 19, 3054-3058.
113. Kaufmann, D.; Pojarová, M.; Vogel, S.; Liebl, R.; Gastpar, R.; Gross, D.; Nishino, T.; Pfaller, T.; Von, A.E. Antimitotic activities of 2-phenylindole-3-carbaldehydes in human breast cancer cells. Bioorg. Med. Chem. 2007, 15, 5122-5136.
114. Zhang, F.; Zhao, Y.; Sun, L.; Ding, L.; Gu, Y.; Gong, P. Synthesis and anti-tumor activity of 2-amino-3-cyano-6-(1H-indol-3-yl)-4-phenylpyridine derivatives in vitro. Eur. J. Med. Chem. 2011, 46, 3149-3157.
115. Jacquemard, U.; Dias, N.; Lansiaux, A.; Bailly, C.; Logé, C.; Robert, J.M.; Lozach, O.; Meijer, L.; Mérour, J.Y.; Routier, S. Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5- phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents. Bioorg. Med. Chem. 2008, 16, 4932-4953.
116. Nassar, E. Synthesis, (in vitro) antitumor and antimicrobial activity of some pyrazoline, pyridine, and pyrimidine derivatives linked to indole moiety. J. Am. Sci. 2010, 6, 463-471.
117. Ding, H.; Zhang, C.; Wu, X.; Yang, C.; Zhang, X.; Ding, J.; Xie, Y. Novel indole α-methylene-γ- lactones as potent inhibitors for AKT-mTOR signaling pathway kinases. Bioorg. Med. Chem. Lett. 2005, 15, 4799-4802.
118. Kamal, A.; Srikanth, Y.V.; Khan, M.N.; Shaik, T.B.; Ashraf, M. Synthesis of 3,3-diindolyl oxyindoles efficiently catalysed by FeCl3 and their in vitro evaluation for anticancer activity. Bioorg. Med. Chem. Lett. 2010, 20, 5229-5231.
119. Tiwari, R.K.; Singh, J.; Singh, D.; Verma, A.K.; Chandra, R. Highly efficient one-pot synthesis of 1-substituted-1,2,3,4-tetrahydropyrazino[1,2-a] indoles. Tetrahedron 2005, 61, 9513-9518.
120. Tiwari, R.K.; Singh, D.; Singh, J.; Yadav, V.; Pathak, A.K.; Dabur; R.; Chhillar, A.K.; Singh, R.; Sharma, G.L.; Chandra, R.; Verma, A. K. Synthesis and antibacterial activity of substituted 1,2,3,4-tetrahydropyrazino [1,2-a] indoles. Bioorg. Med. Chem. Lett. 2006, 16, 413-416.
121. Tiwari, R.K.; Verma, A.K.; Chhillar, A.K.; Singh, D.; Singh, J.; Sankar, V.K.; Yadav, V.; Sharma, G.L. and Chandra, R. Synthesis and antifungal activity of substituted 1,2,3,4- tetrahydropyrazino[1,2-a] indoles. Bioorg. Med. Chem. 2006, 14, 2747-2752.
122. Wu, Y.S.; Coumar, M.S.; Chang, J.Y.; Sun, H.Y.; Kuo, F.M.; Kuo, C.C.; Chen, Y.J.; Chang, C.Y.; Hsiao, C.L.; Liou, J.P.; et al. Synthesis and Evaluation of 3-Aroylindoles as Anticancer Agents: Metabolite Approach. J. Med. Chem. 2009, 52, 4941-4945.
123. Cihan-Üstündaǧ, G.; Capan, G. Synthesis and evaluation of functionalized indoles as antimycobacterial and anticancer agents. Mol. Divers. 2012, 16, 525-539.
124. Youngsaye, W.; Dockendorff, C.; Vincent, B.; Hartland, C.L.; Bittker, J.A.; Dandapani, S.; Palmer, M.; Whitesell, L.; Lindquist, S.; Schreiber, S.L.; et al. Overcoming fluconazole resistance in Candida albicans clinical isolates with tetracyclic indoles. Bioorg. Med. Chem. Lett. 2012, 22, 3362-3365.
125. Arumugam, N.; Raghunathan, R.; Almansour, A.I.; Karama, U. An efficient synthesis of highly functionalized novel chromeno[4,3-b]pyrroles and indolizino[6,7-b]indoles as potent antimicrobial and antioxidant agents. Bioorg. Med. Chem. Lett. 2012, 22, 1375-1379.
126. Yamuna, E.; Kumar, R.A.; Zeller, M.; Rajendra P.K. J. Synthesis, antimicrobial, antimycobacterial and structure-activity relationship of substituted pyrazolo-, isoxazolo-, pyrimido- and mercaptopyrimidocyclohepta[b] indoles. Eur. J. Med. Chem. 2012, 47, 228-238.
127. Diana, P.; Carbone, A.; Barraja, P.; Montalbano, A.; Parrino, B.; Lopergolo, A.; Pennati, M.; Zaffaroni, N.; Cirrincione, G. Synthesis and Antitumor Activity of 3-(2-Phenyl-1,3-thiazol-4-yl)- 1H-indoles and 3-(2-Phenyl-1,3-thiazol-4-yl)-1H-7-azaindoles. Chem. Med. Chem. 2011, 6, 1300-1309.
128. Urgaonkar, S.; Cortese, J.F.; Barker, R.H.; Cromwell, M.; Serrano, A.E.; Wirth, D.F.; Clardy, J.; Mazitschek, R.A Concise Silylamine Approach to 2-Amino-3-hydroxy-indoles with Potent in vivo Antimalaria Activity. Org. Lett. 2010, 12, 3998-4001.
129. Leboho, T.C.; Michael, J.P.; van Otterlo, W.A.; van Vuuren, S.F.; de Koning, C.B. The synthesis of 2- and 3-aryl indoles and 1,3,4,5- tetrahydropyrano[4,3-b]indoles and their antibacterial and antifungal activity. Bioorg. Med. Chem. Lett. 2009, 19, 4948-4951.
130. Giraud, F.; Loge, C.; Pagniez, F.; Crepin, D.; Barres, S,.; Picot, C.; Le Pape, P.; le Borgne, M. Design, synthesis and evaluation of 3-(imidazol-1-ylmethyl)indoles as antileishmanial agents. Part II. J. Enzyme Inhib. Med. Chem. 2009, 24, 1067-1075.
131. Xu, H.; Lv, M. Developments of Indoles as Anti-HIV-1 Inhibitors. Curr. Pharm. Des. 2009, 15, 2120-2148.
132. Ryu, C.K.; Lee, J.Y.; Jeong, S.H.; Nho, J.H. Synthesis and antifungal activity of 1H-pyrrolo[3,2- g]quinoline-4,9-diones and 4,9-dioxo-4,9-dihydro-1H- benzo[f]indoles. Bioorg. Med. Chem. Lett. 2009, 19, 146-148.